Medindia » Health Press Releases A-Z

Neurocrine Biosciences Presents Phase III Data Analysis Demonstrating that Opicapone Added to Levodopa Resulted in a Significant and Sustained Increase in ON Time without Troublesome Dyskinesia in Parkinson's Disease Patients with Motor Fluctuations

- More than 60% of Patients Treated with Once-Daily Opicapone 50 mg Experienced an Increase in Total ON Time of One Hour or Longer